GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genexine Inc (XKRX:095700) » Definitions » Gross Profit

Genexine (XKRX:095700) Gross Profit : ₩-120 Mil (TTM As of Mar. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Genexine Gross Profit?

Genexine's gross profit for the three months ended in Mar. 2024 was ₩-273 Mil. Genexine's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-120 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Genexine's gross profit for the three months ended in Mar. 2024 was ₩-273 Mil. Genexine's Revenue for the three months ended in Mar. 2024 was ₩2,073 Mil. Therefore, Genexine's Gross Margin % for the quarter that ended in Mar. 2024 was -13.16%.

Genexine had a gross margin of -13.16% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage

During the past 13 years, the highest Gross Margin % of Genexine was 86.36%. The lowest was -2.07%. And the median was 64.46%.

Warning Sign:

Genexine Inc gross margin has been in long-term decline. The average rate of decline per year is -21.1%.


Genexine Gross Profit Historical Data

The historical data trend for Genexine's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genexine Gross Profit Chart

Genexine Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7,453.29 11,676.79 31,806.49 11,363.06 387.49

Genexine Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 234.80 205.03 -150.92 98.58 -272.93

Competitive Comparison of Genexine's Gross Profit

For the Biotechnology subindustry, Genexine's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genexine's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genexine's Gross Profit distribution charts can be found below:

* The bar in red indicates where Genexine's Gross Profit falls into.



Genexine Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Genexine's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=4426.627 - 4039.142
=387

Genexine's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=2073.219 - 2346.149
=-273

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-120 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Genexine's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=-273 / 2073.219
=-13.16 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Genexine  (XKRX:095700) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Genexine had a gross margin of -13.16% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage


Genexine Gross Profit Related Terms

Thank you for viewing the detailed overview of Genexine's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Genexine (XKRX:095700) Business Description

Traded in Other Exchanges
N/A
Address
700 Daewangpangyo-ro, Gyeonggi-do, Korea Bio Park Building B, Bundang-gu, Seongnam-si, KOR, 13488
Genexine Inc is a clinical-stage biotechnology company. It is focused on the development and commercialization of immunotherapeutics and next-generation long-acting biologics. Its primary technologies are Therapeutic DNA vaccine technology and Hyfc platform. The company's product pipeline includes products such as GX-H9, GX-E2, GX-G3, GX-G6, and Papitrol-188 among others.

Genexine (XKRX:095700) Headlines

No Headlines